Aurora Cannabis Buys UK Distributor and Pharmacy for £2.1M
ACB sits 51% above its 52-week low of $2.56.
Summary
Aurora Cannabis acquired two UK companies for £2.1 million to expand its medical cannabis distribution and pharmacy capabilities in the UK market.
Key Events · M&A and Partnerships · ACB
-
UK Acquisition Completed
Aurora acquired 100% of Internode Pharma Limited and HAP Pharma Limited for £2.1 million in cash, gaining a licensed importer/wholesaler and a virtual pharmacy in Birmingham, UK.
-
Strategic Expansion
The acquisition provides direct ownership of the UK supply chain from cultivation to patient delivery, reducing reliance on third parties and supporting market share growth in the UK medical cannabis market.
-
Financial Impact
The transaction is expected to be accretive to adjusted EBITDA in future quarters due to operational efficiencies and reduced third-party distribution costs.
-
Hostile Takeover Context
This acquisition comes amid Curaleaf's hostile takeover bid at US$4.00 per share, potentially strengthening Aurora's standalone value and negotiating position.
Analysis · ACB · Life Sciences
Aurora Cannabis has acquired Internode Pharma Limited and HAP Pharma Limited for £2.1 million in cash, securing direct control of UK medical cannabis distribution and a virtual pharmacy. The move expands its international footprint and is expected to be accretive to adjusted EBITDA. While modest in size, the deal is strategically significant amid the ongoing hostile takeover bid from Curaleaf, as it bolsters Aurora's standalone value.
How filings like this one have moved
In the 30 days to Aug 22, 2026, 29.1% of the 2960 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $3.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $251M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.